Adenovirus clinical trials at UCSF
2 in progress, 1 open to new patients

  • The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation

    open to eligible people ages 2 months to 17 years

    This study is designed to assess the safety, overall tolerability, and antiviral activity of "short course" BCV therapy, as compared with current standard of care (SoC), for the treatment of adenovirus (AdV) infections in high-risk (i.e., T cell depleted) pediatric allogeneic hematopoietic cell transplant (HCT) recipients. A virologic response-driven approach to the duration of treatment will be evaluated, in which subjects randomized to BCV therapy are treated until AdV viremia is confirmed as undetectable or until a maximum of 16 weeks of therapy, whichever occurs first.

    San Francisco, California and other locations

  • Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

    Sorry, not accepting new patients

    Provide patients with serious AdV infection or disease access to treatment with BCV.

    San Francisco, California and other locations

Last updated: